国泰中证沪港深创新药产业ETF(517110)财务指标
| |
2024-12-31 |
2024-06-30 |
2023-12-31 |
2023-06-30 |
| 本期已实现收益 |
-18,315,307.95 |
-11,895,370.48 |
-16,690,793.16 |
-6,054,094.98 |
| 本期利润 |
-29,438,160.59 |
-51,033,033.76 |
-25,011,074.04 |
-26,098,580.58 |
| 加权平均基金份额本期利润 |
-0.09 |
-0.17 |
-0.10 |
-0.12 |
| 本期加权平均净值利润率(%) |
-17.62 |
-34.18 |
-15.41 |
-16.84 |
| 本期基金份额净值增长率(%) |
-15.46 |
-28.40 |
-13.89 |
-14.80 |
| 期末可供分配利润 |
-241,599,536.67 |
-178,137,120.27 |
-115,827,191.77 |
-109,596,749.18 |
| 期末可供分配基金份额利润 |
-0.49 |
-0.57 |
-0.40 |
-0.40 |
| 期末基金资产净值 |
250,498,988.33 |
134,961,404.73 |
175,271,333.23 |
161,501,775.82 |
| 期末基金份额净值 |
0.51 |
0.43 |
0.60 |
0.60 |
| 基金份额累计净值增长率(%) |
-49.10 |
-56.89 |
-39.79 |
-40.43 |
微信公众号
证券之星APP
基本资料
